Specific immunotherapy with SQ standardized grass allergen tablets in asthmatics with rhinoconjunctivitis

Background:  The best way to prevent allergy symptoms is to treat the allergic condition. Specific immunotherapy with grass allergen tablets 75 000 SQ‐T (Grazax ® Phleum pratense , ALK‐Abelló) is safe and efficacious in rhinoconjunctivitis patients. As rhinoconjunctivitis often co‐exists with asthma, we aimed to confirm safety and efficacy in grass allergic subjects with asthma and rhinoconjunctivitis. Methods:  A randomized, double‐blind, placebo‐controlled, multicentre trial was performed 10–14 weeks prior to and during the grass pollen season 2004. About 114 subjects were randomized 2 : 1 to grass allergen tablets or placebo. The primary end points were average asthma medication and symptom scores during the grass pollen season, and secondary variables were average rhinoconjunctivitis symptom and medication scores during the grass pollen season. Additionally, number of well days was defined post hoc . Results:  Differences in asthma medication and symptom scores between the treatment groups were negligible. The mean difference in asthma medication score was below 0.1 and 0.3 for asthma symptom score [a single inhalation of salbutamol (200  μ g) was scored 2]. No serious adverse events were reported. A reduction in rhinoconjunctivitis symptom score of 37% ( P  = 0.004) and a 41% ( P  = 0.036) reduction in medication score was found in the grass pollen season for subjects treated with the grass allergen tablet compared with placebo. Well days increased by 54% ( P  = 0.002). Conclusions:  Self‐administration of the grass allergen tablet was safe. The treatment did not impair asthma control and confirmed considerable symptom prevention and reduced medication use. It addresses the allergic condition and represents a baseline treatment for grass pollen allergy.